Nov. 14 at 8:05 PM
$CYCN @skyrockets_Inc Larry🦜🤓 is back. 🧵
As disclosed in Cyclerion’s (CYCN) 10-Q filed November 12, 2025, the Option to License Agreement with CVCO for Olinciguat was terminated, and all rights to the molecule reverted fully to Cyclerion. Under the terms of a standard option agreement, CVCO held only the right to exercise a license but typically would not obtain rights to develop, commercialize, or move the molecule into clinical studies prior to exercising the option. While some option agreements may include limited interim development rights during the option period, any such rights would terminate upon termination of the option agreement unless explicitly preserved through survival provisions or a separate standalone agreement. Consequently, CVCO’s August 21, 2025 press release announcing progression of the molecule into a Phase 2 study with Karolinska Institute raises significant questions about the legal basis for that development activity,……
